Article (Scientific journals)
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
Louis, Edouard; Vermeire, S.; Rutgeerts, P. et al.
2002In Scandinavian Journal of Gastroenterology, 37 (7), p. 818-824
Peer Reviewed verified by ORBi
 

Files


Full Text
A Positive Response to Infliximab in Crohn Disease... 2002-Sc-J-Gastro -traité OCR.pdf
Author postprint (176.87 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Crohn disease; genetics; infliximab; tumour necrosis factor
Abstract :
[en] Background: Two-thirds to three-fourths of patients with either refractory luminal or fistulizing Crohn disease respond to infliximab treatment. The ability or inability to respond seems to persist over time. Biological characteristics and/or genetic background can influence the response to treatment. The aim was to assess the value of C-reactive protein and TNF-alpha serum levels before treatment as well as the TNF -308 gene polymorphism in the prediction of response to infliximab treatment in Crohn disease. Methods: Two-hundred-and-twenty-six Crohn disease patients treated in the setting of an expanded access programme to infliximab in Belgium were studied. There were 136 refractory luminal diseases and 90 refractory fistulizing diseases. Luminal diseases were treated with one single infusion; fistulizing diseases with three infusions at weeks 0, 2 and 6. A clinical response to treatment was defined as either a Crohn disease activity index <150 (complete) or a drop of 70 points (partial) at week 4, for luminal disease, and as either complete fistula healing (complete) or a decrease of at least 50% of the number of draining fistulas on two consecutive visits between weeks 0 and 18, for fistulizing disease. CRP and serum TNF-α levels were measured at week 0 before treatment and were compared between responders and non- responders. Patients were genotyped for the -308 TNF gene polymorphism, and allelic as well as genotype frequencies were compared between responders and non- responders. Results: There were 73.2% responders (46.4% complete and 26.8% partial) and 26.8% non- responders. Response rates were similar in luminal and fistulizing diseases. CRP level before treatment was significantly higher in responders than in non-responders (16.8 mg/l (5-160) versus 9.6 mg/l (5-143); P = 0.02). Furthermore, response rate was significantly higher in patients with elevated CRP (> 5 mg/l) than in patients with a normal CRP value (< 5 mg/l) before treatment (76% versus 46%; P = 0.004; OR: 0.26 (0.11-0.63)). Allelic and genotype frequencies for -308 TNF gene polymorphis m were not significantly different between responders and non- responders - with the exception of a slightly higher TNF2 frequency in nonresponders in luminal disease (22.1% versus 11.6%; P = 0.04). However, this was not associated with a significant difference in genotype frequencies. Conclusion: A positive clinical response to infliximab was associated with a higher CRP level before treatment in our population of Crohn disease patients, but there was no relevant association with -308 TNF gene polymorphism. We therefore suggest that CRP level may help to identify better candidates for infliximab treatment.
Disciplines :
Rheumatology
Gastroenterology & hepatology
Author, co-author :
Louis, Edouard  ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Vermeire, S.
Rutgeerts, P.
De Vos, M.
Van Gossum, A.
Pescatore, Pierre ;  Université de Liège - ULiège > Relations académiques et scientifiques (Droit)
Fiasse, R.
Pelckmans, P.
Reynaert, H.
D'Haens, G.
Malaise, Michel ;  Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Belaiche, Jacques ;  Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Language :
English
Title :
A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism
Publication date :
July 2002
Journal title :
Scandinavian Journal of Gastroenterology
ISSN :
0036-5521
eISSN :
1502-7708
Publisher :
Taylor & Francis As, Oslo, Norway
Volume :
37
Issue :
7
Pages :
818-824
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 09 November 2009

Statistics


Number of views
827 (2 by ULiège)
Number of downloads
639 (1 by ULiège)

Scopus citations®
 
269
Scopus citations®
without self-citations
237
OpenCitations
 
16

Bibliography


Similar publications



Contact ORBi